In Acquisition By Opko, Prolor Poised To Become U.S. Firm’s Biologics Subsidiary
This article was originally published in The Pink Sheet Daily
Executive Summary
Opko’s third investment in the Israeli biopharmaceutical sector is a $480 million all-stock deal in which it will acquire Prolor Biotech, which specializes in developing longer-acting formulations of approved protein products. Its lead candidate is human growth hormone hGH-CTP, in development for growth hormone deficiency in adults and children.